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Abstract
Background: There are limited research and literature on the trial management challenges encountered in running
adaptive platform trials. This trial design allows both (1) the seamless addition of new research comparisons when
compelling clinical and scientific research questions emerge, and (2) early stopping of accrual to individual comparisons
that do not show sufficient activity without affecting other active comparisons. Adaptive platform design trials also offer
many potential benefits over traditional trials, from faster time to accrual to contemporaneously recruiting
multiple research comparisons, added flexibility to focus on more promising research comparisons via pre-planned
interim analyses and potentially shorter time to primary results. We share here our experiences from a trial management
perspective, highlighting the challenges and successes.
Methods: We evaluated the operational aspects of making changes to these adaptive platform trials and identified both
common and trial-specific challenges. The operational steps and challenges linked to both the addition of new research
comparisons and stopping recruitment following pre-planned interim analysis were considered in our evaluation.
Results: Specific operational challenges in these adaptive platform protocols, additional to those in traditional two-arm trials,
were identified. Key lessons are presented describing some of the solutions and considerations over conducting these trials.
Careful consideration on the practicality of the protocol structure (modular versus single protocol), the longevity and
continuity of trial oversight committees, and having clear clinical and scientific criteria for the addition of new research
comparisons were identified as some of the most common challenges.
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Conclusions: Understanding the operational complexities associated with running adaptive platform protocols is
paramount for their conduct, adaptive platform trials offer an efficient model to run randomised controlled trials and we are
continuing to work to reduce further the effort required from an operational perspective.
Trial registration: FOCUS4: ISRCTN Registry, ISRCTN90061546. Registered on 16 October 2013. STAMPEDE: ISRCTN Registry,
ISRCTN78818544. Registered on 2 February 2004.
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Background
Adaptive trial designs are increasingly used as an effi-
cient approach to assess research treatments [1–3].
Multi-Arm Multi-Stage (MAMS) trials are one practic-
able design which can contemporaneously assess mul-
tiple research treatments, often with a shared control
arm, and selectively focus on more promising research
comparisons via pre-planned interim analyses with
in-built stopping guidelines [4, 5]. This novel design can
intuitively couple with the assessment of other promi-
sing treatments in a platform protocol (sometimes
known as ‘master protocol’ or ‘living protocol’), initially
or later [6, 7]. Some recognised advantages compared to
traditional designs include: the repeated contribution of
participants, particularly in the control arm; quick initi-
ation of sites to new comparisons; and, in many
instances, reduced cost per comparisons [1, 4–6, 8].
These advantages are increasingly understood by trial-
ists and funders, but little attention has yet been given
to operational and trial conduct aspects in adaptive tri-
als. FOCUS4 (ISRCTN90061546) and STAMPEDE
(ISRCTN78818544) are key examples of implementing
adaptive and platform designs; both trials are sponsored
by the Medical Research Council (MRC), designed and
coordinated from MRC Clinical Trials Unit (CTU) at
UCL; both trial designs are presented in Fig. 1a and b.
FOCUS4 is a multi-site randomised trial programme
using an umbrella design, including biomarker-stratified
and non-stratified comparisons in one protocol. It aims
to investigate novel agents, in double-blinded compari-
sons where possible, for patients with inoperable ad-
vanced/metastatic colorectal cancer (mCRC) [6, 9].
Since initiating in 2014 with two comparisons, FOCUS4
has opened two additional comparisons across three mo-
lecular cohorts and closed another following a pre-
planned interim analysis. STAMPEDE is an international
protocol investigating the efficacy of multiple treatments
in advanced and metastatic prostate cancer. The trial
opened in 2005 with five research comparisons and has
evolved into a ‘platform’ since 2011 with the addition of six
new comparisons; since trial inception, six comparisons
completed recruitment and two were stopped early follow-
ing interim analysis [4]. Both protocols have further com-
parisons in development to address emerging research
questions.
Issues in stopping accrual early are already covered
elsewhere [4]; here, we identify common operational
components, themes and challenges in these trials so
both real and perceived barriers can be overcome and
adaptive designs used more widely.1
Methods
We identified two well-established platform adaptive
protocols at MRC CTU at UCL, STAMPEDE and
FOCUS4, that have already had extensive experience of
adding and dropping comparisons. A core working
group from both trial management teams was formed to
identify key operational components, specific to trial
management and trial conduct perspectives. This wor-
king group included Trial Managers, Clinical Project
Managers and Statisticians, and sought contributions
from representatives of other roles, including the Unit’s
Data Management System team.
Operational components were identified across the
protocols, which are essential to consider when imple-
menting a new research comparison to an ongoing
protocol. These were independently identified by each
member of the core working group discursively using
semi-structured discussions; features for each compo-
nent were discussed and 10 key components agreed
upon for inclusion.
We discuss these components in the order in which
they may unfold from the initial proposal to implemen-
tation of a new research comparison.
Results
Selection of new research comparisons
A new comparison in the STAMPEDE protocol can be
considered from one perspective as starting a new trial, in-
corporated within an existing protocol. The scientific jus-
tification for the new research arms must be as strong as
for any new trial and consideration must be given on
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whether it is most appropriate to do this comparison
within the existing protocol rather than separately in a
new protocol. Broadly, if there is substantial overlap in the
patient group, reference treatment (standard of care), par-
ticipating sites and primary outcome measures,
embedding a new comparison can bring many efficiencies.
A
B
Fig. 1 a STAMPEDE Trial schema. b FOCUS4 Trial schema
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The STAMPEDE trial team developed criteria and a selec-
tion process before STAMPEDE’s first added comparison,
the ‘abiraterone comparison’, activated in November 2011.
These criteria (Table 1) have evolved to guide the addition
of other comparisons and, recently, criteria for
biomarker-stratified comparisons. All comparisons are de-
veloped with the UK National Cancer Research Institute
(NCRI) Prostate Clinical Studies Group and are independ-
ently peer-reviewed, as would be any new trial, by Cancer
Research UK (CRUK), STAMPEDE’s main grant funder.
FOCUS4 was planned from the start to include new
comparisons. It opened in January 2014 with one rando-
mised comparison in a molecularly defined cohort and a
comparison for all patients regardless of the molecular
characterisation to all eligible participants until targeted
agents were confirmed for each of the other three
planned molecular cohort comparisons. The molecular
cohorts have evolved in response to emerging external
knowledge, as have the selection criteria for biomarker-
defined cohorts (Table 1). These selection criteria were
agreed with FOCUS4’s funders, MRC/NIHR Efficacy and
Mechanism Evaluation (EME) Programme and CRUK,
and these principles have guided discussions to consider
each proposed new comparison.
Assessing new comparisons requires continuous dia-
logue with the Trial Management Group (TMG) and
potential external collaborators as well as a clear under-
standing of the available evidence supporting new research
questions. New comparisons are not only sought with
novel pharmacological treatments already tested in the
specific disease type, but repurposed treatments not trad-
itionally used in oncology setting (for example, celecoxib
and aspirin or anti-diabetic drugs such as metformin) have
been considered. These comparisons have been possible
because of the design efficiencies of adaptive platform
protocols, filling a gap in the clinical and scientific land-
scape in clinical research. However, intrinsic operational
challenges emerge each time an additional treatment is
considered. For example, there is potential for a change in
the risks associated within the trial with associated changes
in trial management practice. Further, the availability and
accessibility of these treatments may require complex pro-
curement, manufacturing and packaging processes.
Clinical leadership of new comparisons
Governance structures are important for clinical trials. The
TMG for each trial is responsible for the day-to-day deliv-
ery of the study and should reflect the multidisciplinary
Table 1 MRC CTU at UCL criteria for considering addition of new research comparisons
No. Assessment criteria
General criteria
1. Sound scientific rationale, including a robust biological hypothesis that supports the need to assess in the disease setting
2. Preliminary evidence to support mechanisms of action or activity or, for combinations, synergy in the disease setting being investigated
3. Therapy is as different as possible from other therapies in the trial (past, present and future)
4. Clear path for the trial results to translate into improved clinical care or impact on public health
5. Investigator enthusiasm for the new research arm and ability to recruit patient population
6. Sufficient number of sites could be reasonably expected to meet the requirements to participate
7. Successful independent peer review as for a new study
8. If appropriate, relevant industry partners willing to collaborate and contribute to the trial, if the research comparison involves a pharmaceutical agent
9. Financial sustainability: funding identified and secured to ensure central TMT support in place to support new comparison
10. Future relevance: The results must still be relevant when the trial matures. Other trials are not already under way for this treatment or will not
report sooner unless duplication, replication and/or more data are strongly required
11. Recruitment to new comparison must not jeopardise completion of the ongoing research comparisons
12. No implications for ongoing and future planned comparisons (e.g. overlapping populations of interest, impact on accrual)
Biomarker-specific criteria
13. Preliminary evidence to support the claim that a particular class of drug or specific agent has mechanisms of action or clinical activity that
identifies it as a candidate within the biomarker defined subgroup. Acceptable data include:
• evidence that targeting the driver pathway in the biomarker defined subgroup results in preclinical and or clinical evidence of activity;
• strong epidemiological evidence of a link between an agent and a biomarker defined subgroup;
• preclinical data to support a synthetic lethal interaction between a biomarker defined subgroup and an agent;
• clinical data from a different disease setting for drug activity in a defined biomarker subgroup
14. Biomarker assay characteristics: Technical ability to test for the biomarker, reproducibly with establishment of an SOP for assessment of the
biomarker, with clear positive and negative controls and a quality assurance programme established between the biomarker laboratories
15. Biomarker operating characteristics: Prevalence of biomarker likely to be sufficient to define an achievable population
16. Prognostic and predictive effects are sufficiently well understood
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and evolving nature of platform protocols. While the Chief
Investigator (CI) is appointed by the Sponsor for the over-
all clinical leadership to the trial platform, other appropri-
ately qualified investigators can share these responsibilities
for specific comparisons and provide the required clinical
oversight specific to each comparison. Both STAMPEDE
and FOCUS4 have introduced Comparison CIs (CCI) and
Comparison Co-CIs (Co-CCI) for new comparisons, often
someone not already on the TMG. The CCI is responsible
for leading a dedicated subgroup developing the research
question underpinning a new comparison, facilitating its
introduction and championing it across the clinical com-
munity. Specialised advice might also be required; for ex-
ample, the STAMPEDE’s TMG incorporated a
diabetologist when the ‘metformin comparison’ was intro-
duced motivated by the fact that the Investigational Medi-
cinal Product (IMP) is not typically used in oncology
settings and specialised input was warranted. In platform
protocols, TMG charters require regular updating with
CCIs and Co-CIs to confirm roles and responsibilities,
ideally using standard templates [10]. Patient and Public
Involvement (PPI) is required in the TMG to represent the
patient’s voice. STAMPEDE currently has two members
and FOCUS4 both a patient and a carer representative; in
each trial, PPI representatives were present from the first
design meetings onwards [11].
A strong, diverse and collaborative TMG is recognised
as an important asset for these protocols; TMG organi-
cally expand as the science of new treatments emerge,
an essential feature for the adaptive nature of platform
protocols. Capacity-building can be achieved by selecting
emerging researchers as CCIs.
Scientific peer review
Each comparison in a platform protocol must be inde-
pendently scientifically peer-reviewed. The core grant
funder has organised this for STAMPEDE and FOCUS4,
with additional review by the Trial Steering Committee
(TSC), the relevant national disease research committees
(specifically, the NCRI’s Clinical Studies Group in the
UK) and, where relevant, industry collaborators. Pro-
posals for new comparisons and changes to FOCUS4 re-
quire scientific peer review at a Sub-Board meeting that
is represented by both funders (NIHR EME and CRUK)
because they jointly funded the trial. Forward planning
for the FOCUS4 EME Sub-Board meetings has been im-
perative, especially when there are proposals for new
comparisons in the pipeline which also need to be
reviewed by the TSC. Having both of these groups spe-
cific to FOCUS4 and, where possible, membership con-
sistent throughout the life of the trial, were identified as
positive strategies to ensure effective trial oversight.
Before STAMPEDE’s first added comparison (the ‘abi-
raterone comparison’), CRUK had no procedures and
systems for peer review and funding for amendments to
incorporate new comparisons. Through collaborative
dialogue with the funding committee’s Chair and Research
Manager, a process was developed introducing a specific
amendment form for new comparisons. There is now
potential for review of amendments between meetings
(‘out-of-committee review’) where funding is not re-
quested, which can greatly reduce review timelines [12].
Significant engagement early on in the trial by all key
stakeholders has proven invaluable to ensure under-
standing the strategy, aims and design of both protocols.
Funding
Funding for each comparison should be sought from
relevant parties. By pooling them in one shared protocol,
each comparison’s costs can be substantially less than
they would have been as a series of traditional standa-
lone two-arm randomised controlled trials.
CRUK provided overall grant funding for the ‘original
comparisons’ in STAMPEDE and extended this for the
two added comparisons (‘M1|RT comparison’ and ‘met-
formin comparison’) with no obvious industry partner.
NIHR, MRC and CRUK have provided grant funding to
FOCUS4, which was intended to support the initial plat-
form set-up, the original biomarker panel analysis costs
and operational resource for trial conduct through to
completion of the trial in 2020.
Six industry partners have so far contributed to
STAMPEDE (three originally, three subsequently) and
two industry partners have contributed to FOCUS4. In
each case, provision of investigational drugs and distri-
bution costs were sought by the investigators.
Early dialogue with funders, ahead of submission for
peer review, can ensure the necessary flexibility for all
parties. Costing is a particular challenge for adaptive and
platform protocols. The exact timing of the addition of
new comparisons may be envisaged in principle but
dates can slip for practical reasons. Therefore, added
comparisons should be costed separately to ensure the
protocol has adequate support throughout its lifespan.
Biomarker development and cohort selection
Accurate molecular stratification is critical to FOCUS4;
therefore, careful preparation is required. A dedicated
sub-group of the TMG was formed to focus on the bio-
marker protocol development before the trial starting.
Two academic laboratories (Leeds and Cardiff ) process
and analyse tumour samples for biomarkers. To ensure
concordance of results and molecular cohort stratifica-
tion between laboratories, a Quality Assurance (QA)
process was set up for pre-trial and ongoing checks [13].
If the addition of a new research comparison also
requires the assessment of new biomarkers, further
funding for biomarker development may be required.
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Since the initiation of FOCUS4, the definition of the
molecular cohorts has changed, new biomarkers have
been added and there have been improvements to the
analysis methodology used to detect genetic mutations.
Implementation of these changes posed logistical chal-
lenges; hence, the following were considered before
making the changes:
◦ Development time and cost for new biomarker assays
in the laboratories;
◦ Cross-laboratory QA [13], specifically for new bio-
markers and new analysis methodologies;
◦ Timing of implementation of changes to the biomarker
panel.
Practically, changing the molecular cohort definition
with existing biomarkers has an impact on the random-
isation algorithm (as presented in our companion paper
on the data management perspective) and has implica-
tions for the statistical analyses. A change in biomarker
analysis methods also requires QA before being imple-
mented for the trial and careful planning to ensure
cost-effectiveness at the laboratories. Coordination of
the biomarker panel development with regulatory appli-
cation and implementation at sites can be challenging
and therefore thorough preparation and constant review
of timelines is required to ensure successful delivery of
new comparisons.
STAMPEDE introduced biomarker screening of meta-
static patients in selected centres in 2017, in anticipation
of a molecularly stratified comparison in 2018. It had
already demonstrated feasibility with a phenotypically
defined research comparison within the overarching pa-
tient population (the ‘M1|RT comparison’).
Protocol development
The FOCUS4 and STAMPEDE protocols have taken dif-
ferent approaches to protocol structure. For both trials,
the protocols were based on the same template (MRC
CTU at UCL protocol template, in line with the SPIRIT
guidelines [14]). Using a template helps to ensure
consistency in protocol structure.
The STAMPEDE protocol is structured as a single
protocol and sections are amended when a new research
comparison is added to include comparison-specific de-
tails (notably, to rationale, eligibility, treatment and sta-
tistics). As the trial has evolved, sections have been
edited to reduce the detail on research comparisons no
longer recruiting or treating patients, so the protocol
primarily contains information that is current and there-
fore more relevant to the clinical management of study
participants.
The FOCUS4 protocol uses a modular structure with
a master protocol and separate comparison-specific
protocols, each independently version-controlled to fa-
cilitate a straightforward update process when compari-
son-specific changes are made to the protocol.
Maintaining consistency of information across protocol
documents can be challenging. This is a particular issue
for the modular approach used by FOCUS4, as often
amendments must be made to specific ‘modules’ at differ-
ent times.
A modular protocol structure may be more user-
friendly, especially where some sites are not treating
patients in all open research comparisons of the trial, as
is the case in FOCUS4. This structure has sometimes
been hampered key stakeholders’ understanding that
FOCUS4 is a single protocol; this was a particular
issue for the Ethics Committee (EC) and Competent
Authority (CA).
Both approaches to protocol structure have merits and
disadvantages; we therefore advise adequate discussion
within the TMG to attempt to future-proof this crucial
document. Explaining the rationale on the chosen proto-
col in the cover letter to EC and CA could also pave the
way for a clearer review process by the research autho-
rities and ultimately minimise delays that additional
questions might otherwise raise.
Ethics and regulatory assessment and version control
One key efficiency of platform approaches is the quicker
initiation time achieved by adding new research compar-
isons through a substantial amendment compared to the
traditional approach. The EC and CA in the UK have
been open to reviewing and approving amendments re-
lating to the addition of a new research comparisons for
both protocols since the initial approvals.
The FOCUS4 team held discussions with EC and CA
staff before the initial applications. This ameliorated
some, but not all, of the challenges when the application
was formally reviewed. Following a regulatory advice
meeting to discuss the FOCUS4 design, leading to a sub-
stantial amendment, the CA accepted the full protocol,
including the principle of future comparisons, under one
Clinical Trial Authorisation (CTA); clarifying full sub-
missions be submitted for each subsequent comparison
added. Similar challenges arose with the EC, which did
not initially accept the submission because of the proto-
col’s structure. FOCUS4 was resubmitted after discus-
sion between the CI and EC chair and the application
restructured to reiterate that FOCUS4 is one protocol.
Clear terminology is particularly important to reinforce
this point; hence ‘comparison’ is used throughout proto-
cols rather than ‘trial’ or ‘sub-trial’. This early work helped
lay the foundations for new research comparisons to be
submitted and approved as amendments to the existing
protocol. The FOCUS4 team decided, for consistency, to
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use the version number and date of the master protocol
section in the amendment documentation, rather than the
version number of the updated, independently version-
controlled module. This necessitates regular reminding to
the EC, CA and sites of this approach.
Although the amendment review process has been
effectively the same for both trials, some comparison-
specific topics have been noted. For example, the re-
search treatment in STAMPEDE’s ‘M1|RT comparison’
was radiotherapy rather than a drug, but still required
CA approval because the protocol includes IMPs in
other comparisons. Discussions with the CA regarding
the documentation requirements for the amendment
were key to guide the submission process for protocol
amendments.
The approval timelines for a substantial amendment
are shorter than those for a new application; however,
the time required collating the documents to submit the
amendment should not be underestimated.
Contracts and drug supply
Like in any trial, prompt set-up of contracts with indus-
try partners is crucial to seamless activation of added
comparisons. In many trials, there is not a single tem-
plate for contract negotiation, which is appropriate given
the potential for bespoke needs for each comparison.
Therefore, contract development can be lengthy, par-
ticularly for more novel agents and around Intellectual
Property. Ensuring the legal teams understand the adap-
tive platform design, to which relatively few yet have
exposure, can help decrease delays. We envisage this will
improve as these designs become more familiar to industry.
Drug supply logistics present operational and contrac-
tual challenges when set up in parallel to active compari-
sons. Delays in signing agreements cause delays in IMP
release for packaging and labelling and subsequent
release to sites. There is a risk that the existing compari-
sons may finish accrual (e.g. target-attained or safety or
efficacy signals), while the added comparisons are in
set-up. This would require temporary suspension of
recruitment to the whole platform until the new com-
parison is activated.
Each comparison brings a unique combination of chal-
lenges. The supplier for one FOCUS4 comparison would
not meet FOCUS4’s preference of providing IMP pack-
aged and labelled to sites, but could provide bulk IMP
and matched placebo. Therefore, the CTU had to iden-
tify a separate packager and contract independently with
them. The timelines may be comparable with each
approach, but this approach increased the CTU’s work-
load. The contracting process was smoother for the next
added comparison, using a previous collaborator which
already had a good relationship.
STAMPEDE has several drug supply models, including
separate approaches for the two abiraterone-containing
arms. In its first added research comparison (‘abirater-
one comparison’), abiraterone distribution was arranged
via the manufacturer’s preferred vendor. The third added
research comparison, the ‘enzalutamide + abiraterone
comparison’, required a public tendering process needing
considerable time and attention: finalising the tender;
shortlisting eligible candidates; appointing the successful
bidder. This process had knock-on implications and
delayed the time to activation with a period > 200 days
dedicated to the tendering process. This particular
aspect is not uniquely required for adaptive platform
protocols and could be a key activation step for the
launch of any clinical trial of investigational medicinal
products requiring packing and manufacturing activities.
However, timelines can be significantly be affected by
contract negotiation and EU tendering timelines; it is
therefore essential to carefully consider implications on
other research arms.
Case report forms and database changes
Case report forms (CRFs) need to be appropriate to the
comparisons. Therefore, adding a new research compari-
son can involve additions to, or additional, CRFs and re-
view and update of all data management systems
including and trial database. The operational steps for
this are described in greater detail in our companion
paper on data management in adaptive platform proto-
cols (co-submitted).
Site implementation
One key difference between STAMPEDE and FOCUS4
is the governance framework under which they were ini-
tiated. STAMPEDE, opened in October 2005, has seen
changes in UK governance frameworks (COREC, NRES,
HRA) and has not been permitted to adopt the coordi-
nated local approval system brought in by NIHR Coordi-
nated System for gaining NHS Permission (NIHR CSP);
therefore, site activation follows an ad-hoc, trial-specific
model. FOCUS4’s more recent inception meant the trial
started under the NIHR CSP framework, where site
acceptance for amendments may be assumed after a
35-day review period for trusts in England.
Both trials use a risk-based approach to decide which
actions sites needs to complete before local implementa-
tion and opted for a site implementation model using
pre-specified activation requirements (Table 2). Once all
regulatory approvals are received for a substantial
amendment, the central team provides sites activation
pack with a timeframe to fulfil all comparison-specific
activation requirements and gain local approval.
In FOCUS4, these requirements may also depend on
the site level, as all sites identify and approach patients,
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Table 2 Summary of key site-activation steps for new comparisons
Activation steps Participating centres Trial team to consider
Acceptance of substantial
amendment
NHS Trust R&D to review and approve
amendment; this may include:
• R&D approval/Letter of no objections
• signed confirmation from Principle investigator, Research Nurse, Pharmacy
• National requirements for NHS
Management approval
• CTU SOPs on Site Activation
• Requirement for mNCA variation
Site training Attendance to trial training may be required by:
• Site Principle Investigator
• Clinical Research team (research nurse, local coordinators, data managers)
• Pharmacist
• Site-specific requirements based on level
of participation (Patient Identification
Centres, Randomising centre, follow-up
only)
• Development of comparison specific
training material
• Risk-based consideration for training
documentation (self-declared, certificates)
• Type of training (in person, teleconference)
Localise patient-related
documents
Comparison specific PIS, CF and GP letters to be localised by each site • Risk-adapted approach for verification of
localised material (site confirmation of
documents on headed paper vs emailing
copies of documents on local headed
paper for verification by trial team)
Update local investigator,
pharmacy site file and site
manuals
Sites to confirm (by signing and returning trial-specific confirmation to CTU
trial team):
• site file updated
• updated trial manuals read and understood
• Updated indexes for files sent to sites to
include comparison specific documents
• trial manuals (i.e. Sample Handling and
pharmacy manuals) to be updated and
circulated before site activation
CF consent form, RN research nurse, PIC Patient Identification Centre, PIS Patient Information Sheet, SOP Standard Operating Procedure, TMT Trial
Management Team
Fig. 2 FOCUS4 site evaluation and site level classification
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even if not randomising or treating them in all compari-
sons (Fig. 2). Key to successful site activation was en-
gaging with investigators sites as early as possible with
email circulars and open Q&A sessions to ensure sites
were aware of protocol changes and to allow time for in-
ternal feasibility.
STAMPEDE has had a shared control arm for non--
biomarker-stratified comparisons, implemented in a sin-
gle randomisation system. Therefore, activation had to
be simultaneous across all sites. Sites not meeting all ac-
tivation requirements, after several weeks’ notice, were
temporarily suspended from recruitment until these
were in place.
Each molecular cohort comparisons in FOCUS4 has a
dedicated control arm; sites not meeting the activation
requirements by the pre-set launch date were delayed
from recruiting only to the new comparison and could
continue registration and randomisation to other exis-
ting comparisons. The FOCUS4 team found this a
labour-intensive operational process to manage, because
it required manual tracking of activation status for sites.
Due to the often-novel nature of agents being consi-
dered for inclusion, the FOCUS4 selection process
includes a safety assessment considering the delivery of
a comparison across a widely dispersed collaborative
group of sites. The FOCUS4 TMG agreed three levels of
site participation, with all sites assessed before accredit-
ation with level-specific selection criteria to account for
site facilities and experience in using novel agents. Most
novel agents are most appropriately administered at
Experimental Cancer Medicine Centres (ECMCs) or
sites assessed to have equivalent experience (FOCUS4
Level 3 site). Patients at any FOCUS4 site may be identi-
fied as suitable to consider a molecular cohort compa-
rison using a novel agent according to their biomarker
panel results and may need referral to a Level 3 site to
be randomised. The likely burden for patients is consi-
dered during the selection process for new comparisons.
Additional comparisons were implemented in STAM-
PEDE without major issues. Sites reacted constructively
and adapted quickly to the change showing great sup-
port; an average of 70% of centres have been ready on
the day of the launch. The impact of having many sites
ready to recruit to the one randomisation on activation
data is demonstrated in Fig. 3 which shows the time to
recruitment of comparison-eligible patients is much
quicker for the additional comparisons than the original
comparisons. The trial took five years to have 80 centres
randomise ≥ 1 patient; the first four added comparisons
had > 80 centres randomise ≥ 1 suitable patient within
Fig. 3 Time (months) to first new patient randomised for each STAMPEDE research comparisons. The ‘original comparisons’ (pale blue) opened
slowly, deliberately activating few centres in the first 18 months, during a phase to understand acceptability of randomisation and any key
toxicity signals. The ‘M1|RT comparison’ (green) only applied to a subset of patients defined by whether they have metastatic disease (~60%). The
‘tE2 comparison’ (gold), which started most recently, also applies only to a subset of patients, defined strictly by any treatment to which they
have been exposed between diagnosis and randomisation
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3–4 months after activation. This is uncommonly quick
for any trial and it is one key, practical strength of taking
new comparisons into existing protocols. Each cohort
has a different prevalence in FOCUS4, so this metric is
less appropriate as a summary measure.
An implementation model for the addition of a new
research comparison needs to balance regulatory, go-
vernance, CTU policies and SOPs as well as site capacity
and capability. A one-size-fits-all approach is therefore
not recommended and the TMG and TMT should think
carefully about which model to adopt. An ongoing dia-
logue with participating centres in the months leading
up to the addition of a new comparison as well as close
collaboration with the trial delivery bodies (e.g. NIHR
CRN in UK) has proven to be key to effectively commu-
nicating future changes and the detail of implementation
plans, ultimately resulting into the success of these adap-
tive platform protocols.
The enthusiasm of research sites for a new comparison
requires prior gauging before scientific peer review and
funding has taken place to ensure a thorough initial
feasibility assessment; this can be done quickly and inex-
pensively via online surveys, with discussion reinforced
at in-person or online investigators meetings and Q&A
sessions. Significant engagement early in the trial by all
key stakeholders has proven invaluable to ensure under-
standing not only of the design but also of the strategy
and aims of both protocols. It is therefore important to
embed a clear communication and dissemination plan
for the implementation of all new research comparisons.
Short editorials published in peer-review journals are
one way these trials have found to engage with the cli-
nical and research community at large and to raise the
profile and visibility of the trial platforms [15–18].
Further considerations on trial conduct
Regular workload prioritisation exercises are advised to en-
sure efficient conduct; a major main trial management
challenge is to balance conflicting tasks of running open
comparisons while setting up new ones and, in time, clos-
ing out older ones. For example, data chasing and chasing
for pre-planned interim analyses for ongoing research
comparisons might coincide with activation of a new re-
search comparison, competing for the trial team’s time or
results meetings for final analyses may coincide with grant
submissions for new comparisons. Indeed, the initial safety
analysis for STAMPEDE’s ‘enzalutamide + abiraterone
comparison’ was due six weeks after the comparison’s
100th randomisation; the high rates of accrual expected for
this new comparison meant that the all CRFs and database
changes had to be ready before the comparison’s activation
date, whereas a separate, new, slower-recruiting trial could
have afforded a more phased approach to CRF and data-
base changes implementation. Data for this comparison
needed to be actively pursued from sites to ensure timely
IDMC review with patient safety being paramount.
The dynamic and adaptive nature of these trial plat-
forms can also lead to the selective discontinuation of
recruitment in a particular group cohort. For example,
when recruitment to the ‘abiraterone comparison’ was
completed, the only open comparison included only a
subset of potential patients: only suitable for newly diag-
nosed metastatic patients for six months until the
‘metformin comparison’ was activated. This gap was lar-
ger than originally envisaged because of faster-than-an-
ticipated accrual and operational challenges in activating
the new comparison. Similarly, the stage I analysis for one
of FOCUS4’s ‘original comparisons’ was triggered very
shortly after a new research comparison was activated
which pressured the trial team.
It is essential to appreciate how overall changes in plat-
form protocols can affect the launch of a new comparison.
For example, positive primary results from the STAM-
PEDE ‘original comparisons’ in 2016 provoked updates to
the backbone standard of care [19, 20]. This required a
substantial amendment to the protocol, rightly delaying
activation of the ‘metformin comparison’.
Estimating the operational resources required for a
platform protocol is challenging, not least because of dif-
ficulties in forecasting how long each comparison might
be open. Continuity of trials unit staff is very helpful and
having more experienced staff facilitates a more stream-
lined approach work and to workload division whereby
where less training and mentoring is required.
Trial oversight is not only limited to the TMG and the
commitment of members of the Independent Data Moni-
toring Committee (IDMC; all independent members) and
the TSC (some independent members) has been a strength
for these trials. The TSCs have provided impartial input to
decisions on whether to add new research comparisons,
with particular attention on how this would affect the in-
tegrity of existing comparisons. The longevity of the proto-
col means more meetings over time. FOCUS4 appointed a
larger-than-usual membership, including two statisticians,
allowing greater ease of assuring quoracy while anticipating
scheduling difficulties for frequent meetings.
Independent oversight committees often include expe-
rienced researchers, later in their careers. Some commit-
tee members may retire in a trial that runs for many
years and may need replacing. Protecting the continuity
of the membership can be challenging in protocols of
this magnitude, with the trial management teams nee-
ding to ensure all members are fully informed at all
times on the protocols and any forthcoming changes.
Discussion
Adaptive platform and umbrella protocols offer several
practicable and desirable benefits which facilitate speedier
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answers and allow clinical trials to serve as a tool to move
treatment on for patients much more quickly. There are
notable operational challenges which require careful atten-
tion. Our paper reflects on some of the challenges encoun-
tered during the implementation process and crystallises
our experience in the conduct of adaptive platform and
umbrella protocols. Our experiences in STAMPEDE and
FOCUS4 detailed in the sections above, offer some key
learning points which are summarised in Table 3.
A major challenge posed by running these adaptive
platform and umbrella protocols is not introduced by
the operational steps for the addition of a new research
comparison per se, but balancing these activities against
the needs of the ongoing comparisons. This was identified
as a distinctive feature of this trial design, introducing a
new management element over and beyond those posed
by traditional two-arm trial designs. This is further
presented in Fig. 4 as an example of the multiple, compet-
ing activities that required ongoing re-prioritisation and
assessment.
Further work is required to improve processes and op-
erational efficiencies to trial management so to deliver
high-impact trials. Team processes need to be in place
to ensure tasks are distributed appropriately and with
clear communication so to ultimately successfully deli-
vering adaptive platform protocols.
The use of shared resources across multiple compari-
sons must be cost-saving compared to separate two-arm
non-adaptive trials to address the same questions. Efforts
are required by trials units to develop costing models
Table 3 Trial conduct: lessons learned on adding a new research comparison to an ongoing platform
Area Lesson learned
Research question Define criteria for review of new research comparison
Trial Management Group Collaborative Group
Chief Investigator: overall trial oversight
Co-CI: clinical and scientific leadership for addition of new research comparison
Scientific peer review Ongoing discussion with key funding stakeholders
Planning for adequate support of central resources
Addition of new comparison discussed in early stages to assess feasibility of funding
Biomarker development Clearly define cohort and identify biomarkers
Early feasibility assessment for site implementation
Protocol development Consider protocol structure to futureproof changes in trial design (e.g. modular vs single protocol)
Ethics and regulatory approval Rationale for addition of new comparison discussed early with regulatory bodies to prepare for submission
Change of governance and regulatory framework
CRF and database development Timelines for implementing changes are key for timely implementation
Site implementation Engage early (e.g. via survey or Q&A) to gauge interest in new research question
Discuss activation criteria with centres as early as possible
Pre-set timelines for local approval of new comparison (if control arm is shared)
Other Constant assessment of priorities and competing tasks
Importance of adequate resourcing of central trial management team
Consider recruitment rate to plan for post-launch activities (e.g. pre-planned interim analyses)
Fig. 4 Selected STAMPEDE trial activities between March 2015 and September 2016 (research comparison addition, standard-of-care change,
research comparison closure, general trial management)
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which can express expected costs and anticipated savings
to funding bodies [8].
Recognising the capacity of sites for platform protocols
is also paramount to improve trial conduct. Participating
centres have dedicated enormous work to implement tri-
als like STAMPEDE and FOCUS4 and more dialogue is
needed with hospitals, ethics committees (e.g. via HRA
in UK) and trial delivery bodies (e.g. NIHR CRN in UK)
on the delivery of adaptive platform protocols.
More CTUs are identifying opportunities to conduct col-
laborative, adaptive platform protocols, including, in the UK,
COMPARE in head and neck cancer (ISRCTN41478539),
Precision-Panc in pancreatic cancer (http://www.precision-
panc.org/our-research/current-research/), Lung-MATRIX
(NCT02664935). Each new protocol will present a unique
combination of challenges. By sharing experiences, will fur-
ther improve operational efficiencies.
Endnotes
1Our lessons learnt from a central data management
perspective are reported in our companion paper ‘Oper-
ational aspects of adaptive platform protocols’.
Abbreviations
CA: Competent authority; CCI: Co-Chief Investigator; CI: Chief Investigator;
CoCCI: Co-Comparison Chief Investigator; COREC: Central Office of Research
Ethics Committees; CRF: Case report form; CRUK: Cancer Research UK;
CSG: Clinical Studies Group; CSP: Coordinating System for gaining NHS
Permission; CTU: Clinical Trials Unit; EC: Ethics Committee;
ECMC: Experimental Cancer Medicine Centre; EME: Efficacy and Mechanism
Evaluation; FOCUS4: Molecular selection of therapy in colorectal cancer: a
molecularly stratified randomised controlled trial programme; HRA: Health
Research Authority; mNCA: Model Non-Commercial Agreement;
MRC: Medical Research Council; NCRI: National Cancer Research Institute;
NIHR: National Institute for Health Research; NRES: National Research Ethics
Service; PPI: Patients and Participant Involvement; QA: Quality assurance;
SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials;
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer:
Evaluation of Drug Efficacy; TMG: Trial Management Group; TSC: Trial
Steering Committee; UCL: University College London
Acknowledgements
The authors would like to acknowledge the contribution and input from
past and current STAMPEDE and FOCUS4 TMG members, as well as key
members of the MRC CTU at UCL, Sharon Love, Lindsey Masters, Dominic
Hague and Stephen Townsend.
Funding
The FOCUS4 Trial Programme is jointly funded by the MRC-NIHR Efficacy and
Mechanism Evaluation Programme (11/100/50) and Cancer Research UK
(A13363). Medical Research Council (Methodology 171339, Cancer Speeding
Therapeutics development 171339 and Cancer Stratified medicine & Transla-
tion science 171339), Cancer Research UK (162082), Sanofi Aventis Novartis
(158519), Janssen (163301), Astellas (163026) and AstraZeneca (158046).
Availability of data and materials
Not applicable.
Authors’ contributions
FS: wrote key sections, provided intellectual and practical input, agreed to
final version. RB: wrote key sections, provided intellectual and practical input,
agreed to final version. KL: wrote key sections, provided intellectual and
practical input, agreed to final version. LM: wrote key sections, provided
intellectual and practical input, agreed to final version. CA: provided
intellectual and practical input, agreed to final version. AB: provided
intellectual and practical input, agreed to final version. LB: provided
intellectual and practical input, agreed to final version. MP: originated the
multi-arm multi-stage design, provided intellectual and practical input,
agreed to final version. RL: provided intellectual and practical input, agreed
to final version. RK: provided intellectual and practical input, agreed to final
version. NJ: provided intellectual and practical input, agreed to final version.
TM: provided intellectual and practical input, agreed to final version. CP: pro-
vided intellectual and practical input, agreed to final version. GA: provided in-
tellectual and practical input, agreed to final version. NC: provided
intellectual and practical input, agreed to final version. SG: provided intellec-
tual and practical input, agreed to final version. MS: wrote key sections, pro-
vided intellectual and practical input, agreed to final version. All authors read
and approved the final manuscript.
Ethics approval and consent to participate
The FOCUS4 and STAMPEDE trials have received favourable opinion by the
relevant Research Ethics Committee (13/SC/0111 and 04/MRE07/35).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology,
UCL, 90 High Holborn, London WC1V 6LJ, UK. 2MRC London Hub for Trials
Methodology Research, London, UK. 3Institute of Cancer Research, Sutton,
UK. 4Royal Marsden Hospital, Sutton, UK. 5UCL Cancer Institute, University
College London, London, UK. 6Christie and Royal Salford Hospital,
Manchester, UK. 7Division of Cancer Sciences, University of Manchester and
the Christie, Manchester, UK. 8Kantonsspital St. Gallen, St. Gallen, Switzerland.
9Institute of Cancer and Genomic Sciences, University of Birmingham,
Edgbaston, Birmingham, UK. 10Cancer Research UK/MRC Oxford Institute for
Radiation Oncology, University of Oxford, Oxford, UK.
Received: 10 August 2018 Accepted: 19 January 2019
References
1. Saville BR, Berry SM. Efficiencies of platform clinical trials: A vision of the
future. Clin Trials. 2016;13(3):358–66.
2. Hatfield I, Allison A, Flight L, Julious SA, Dimairo M. Adaptive designs
undertaken in clinical research: a review of registered clinical trials. Trials.
2016;17(1):150.
3. Wason J, Magirr D, Law M, Jaki T. Some recommendations for multi-arm
multi-stage trials. Stat Methods Med Res. 2016;25(2):716–27.
4. Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, et al.
Flexible trial design in practice - stopping arms for lack-of-benefit and
adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage
randomized controlled trial. Trials. 2012;13:168.
5. Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown
L, et al. Testing many treatments within a single protocol over 10 years at
MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella
and basket protocols. Clin Trials. 2017;14(5):451–61.
6. Parmar MK, Carpenter J, Sydes MR. More multiarm randomised trials of
superiority are needed. Lancet. 2014;384(9940):283–4.
7. Woodcock J, LaVange LM. Master protocols to study multiple therapies,
multiple diseases, or both. N Engl J Med. 2017;377(1):62–70.
8. Mawocha SC, Fetters MD, Legocki LJ, Guetterman TC, Frederiksen S, Barsan
WG, et al. A conceptual model for the development process of confirmatory
adaptive clinical trials within an emergency research network. Clin Trials.
2017;14(3):246–54.
9. Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, et al. Inhibition of
EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type
Schiavone et al. Trials          (2019) 20:264 Page 12 of 13
for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised
trial. Lancet Gastroenterol Hepatol. 2018;3(3):162–71.
10. A proposed charter for clinical trial data monitoring committees: helping
them to do their job well. Lancet. 2005;365(9460):711–22.
11. Brueton VC, Vale CL, Choodari-Oskooei B, Jinks R, Tierney JF. Measuring the
impact of methodological research: a framework and methods to identify
evidence of impact. Trials. 2014;15:464.
12. Hearn J, Keat N, Law K, Sharpe R. How Cancer Research UK is adapting to
adaptive designs. Trials. 2011;12(1):A6.
13. Richman SD, Adams R, Quirke P, Butler R, Hemmings G, Chambers P, et al.
Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised
therapy trial. J Clin Pathol. 2016;69(1):35–41.
14. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K,
et al. SPIRIT 2013 statement: defining standard protocol items for clinical
trials. Ann Intern Med. 2013;158(3):200–7.
15. Parker CC, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, et al.
Prostate radiotherapy for men with metastatic disease: a new comparison in
the STAMPEDE Trial. Clin Oncol. 25(5):318–20.
16. Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, et al.
Combining enzalutamide with abiraterone, prednisone, and androgen
deprivation therapy in the STAMPEDE Trial. Eur Urol. 2014;66(5):799–802.
17. Gillessen S, Gilson C, James N, Adler A, Sydes MR, Clarke N. Repurposing
metformin as therapy for prostate cancer within the STAMPEDE Trial
platform. Eur Urol. 70(6):906–8.
18. Gilbert DC, Duong T, Sydes M, Bara A, Clarke N, Abel P, et al. Transdermal
oestradiol as a method of androgen suppression for prostate cancer within
the STAMPEDE trial platform. BJU Int. 2018.
19. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al.
Addition of docetaxel, zoledronic acid, or both to first-line long-term
hormone therapy in prostate cancer (STAMPEDE): survival results from an
adaptive, multiarm, multistage, platform randomised controlled trial. Lancet.
2016;387(10024):1163–77.
20. Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al.
Addition of docetaxel or bisphosphonates to standard of care in men with
localised or metastatic, hormone-sensitive prostate cancer: a systematic review
and meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243–56.
Schiavone et al. Trials          (2019) 20:264 Page 13 of 13
